Considering metformin in cardiometabolic protection in psychosis.

The article offers the authors' insight regarding the use of metformin for the cardiometabolic protection in psychosis. They state that a lifestyle programme to prevent weight gain at initiation of antipsychotic treatment is essential to tackle or prevent cardiometabolic risk. They suggest that the metformin combined with a lifestyle programme could be used for severely mentally ill when antipsychotic agents are initiated.